| Field | Specification |
|---|---|
| Mfr No | |
| Accession Number | |
| Alternative Names | ATP7A, ATP 7A, ATP7A_HUMAN, ATPase Cu transporting, ATPase copper transporting alpha polypeptide, ATPase Cu++ transporting alpha polypeptide (Menkes syndrome), Copper transporting ATPase 1, Cu++ transporting P type ATPase, Menkes disease associated protein, Menkes syndrome, Menke, MC1, MC 1, MK, MNK, DSMAX, SMAX3, OHS, FLJ17790, OTTHUMP00000062077 |
| Cellular Localization | |
| Clonality | |
| Concentration | |
| Host | |
| Immunogen | Synthetic peptide amino acids 42-61 (cytoplasmic C-terminus) of human Copper- transporting ATPase1 |
| Isotype | |
| Product Type | |
| Reactivity | |
| Shipping | |
| Storage | |
| Target |
ATP7A, also known as copper-transporting ATPase 1, is a transmembrane P-type ATPase that plays a critical role in cellular copper homeostasis. It facilitates the export of excess intracellular copper by trafficking it into the secretory pathway for vesicular exocytosis. This function is essential for systemic copper absorption in the intestine and reabsorption in the kidney, processes that are effectively modeled in polarized epithelial systems such as Madin-Darby canine kidney (MDCK) cells.
In the nervous system, ATP7A is indispensable for delivering copper to cuproenzymes involved in neurotransmitter synthesis, antioxidant defense, and mitochondrial function. Disruption of ATP7A-mediated copper transport leads to severe neurodevelopmental consequences, as seen in Menkes disease, a fatal X-linked disorder characterized by copper deficiency, neurodegeneration, and connective tissue abnormalities.
Emerging research links ATP7A dysfunction to broader neurodegenerative processes. Impaired copper regulation contributes to oxidative stress, protein misfolding, and mitochondrial dysfunction—hallmarks of diseases such as Alzheimer’s and Parkinson’s. Moreover, ATP7A expression is altered in various cancers and has been associated with resistance to platinum-based chemotherapies like cisplatin and carboplatin.
Given its dual role in systemic copper regulation and neuronal health, ATP7A is a promising target for therapeutic strategies aimed at restoring metal homeostasis in neurodegenerative diseases. Understanding its regulation and trafficking dynamics may unlock new avenues for intervention in copper-related neuropathologies.
1 µg/ml of SMC-398 was sufficient for detection of Copper-transporting ATPase1 in 20 µg of rat brain lysate by colorimetric immunoblot analysis using Goat IgG:HRP as the secondary antibody.
Cite this product varies by variant:
- SMC-398D — Size: 100 ug: ATP7A Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398D, RRID: AB_11232613)
- SMC-398D-A390 — Size: 100 ug: ATP7A Antibody: ATTO 390 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398D-A390, RRID: AB_2700924)
- SMC-398D-A488 — Size: 100 ug: ATP7A Antibody: ATTO 488 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398D-A488, RRID: AB_2700925)
- SMC-398D-A594 — Size: 100 ug: ATP7A Antibody: ATTO 594 (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398D-A594, RRID: AB_2700927)
- SMC-398D-APC — Size: 100 ug: ATP7A Antibody: APC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398D-APC, RRID: AB_2700933)
- SMC-398D-BI — Size: 100 ug: ATP7A Antibody: Biotin (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398D-BI, RRID: AB_2700934)
- SMC-398D-FITC — Size: 100 ug: ATP7A Antibody: FITC (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398D-FITC, RRID: AB_2700935)
- SMC-398D-HRP — Size: 100 ug: ATP7A Antibody: HRP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398D-HRP, RRID: AB_2700936)
- SMC-398D-PCP — Size: 100 ug: ATP7A Antibody: PerCP (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398D-PCP, RRID: AB_2700938)
- SMC-398D-RPE — Size: 100 ug: ATP7A Antibody: RPE (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398D-RPE, RRID: AB_2700939)
- SMC-398S — Size: 12 ug: ATP7A Antibody (StressMarq Biosciences | Victoria, BC CANADA, Catalog# SMC-398S, RRID: AB_11232613)
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
2. Samimi G., et al. (2004) Mol Pharmacol. 66: 25-32.
3. Greenough M., et al. (2004) Am. J. Physiol. Cell Physiol. 287: C1463-71.
4. Song, I.S., et al. (2004) Mol. Cancer Ther. 3: 1543-1549.
5. van Dongen, E.M., et al. (2004) Biochem. Biophys. Res. Commun. 323: 789-795.
6. Samimi, G., et al. (2004) Mol Pharmacol 66: 25-32.
7. Morgan, C.T., et al. (2004) J. Biol. Chem. 279: 36363-36371.
8. Barnes, N., et al. (2005) J. Biol. Chem. [Epub].